New Discoveries in Liver Disease in Central Tokyo
Division of Hepatology - Tokyo Metropolitan Komagome Hospital
Tokyo Metropolitan Komagome Hospital was established in 1879 and was originally intended to treat the spread of infectious disease. Over the years its focus has broadened to become one of Japan's foremost cancer hospitals. The hospital is dedicated to providing top quality patient care alongside cutting edge basic and clinical research, and the Division of Hepatology is no exception to this.
Doctors are dedicated to the diagnosis, treatment, and clinical research of liver diseases, especially viral hepatitis, liver cirrhosis and cancer. They excel at Direct acting antiviral (DAA) treatment for Hepatitis C, as well as Radiofrequency Ablation (RFA) therapy for liver cancer, while also conducting basic research into liver fibrosis, aiming at development of new drugs for liver diseases.
After demonstrating the potential anti-fibrotic effect of Wnt inhibitor PRI-724, the drug was taken into Phase 1 clinical trial, which also had encouraging results. With this, and ongoing and potential trials in the future, the Division is well equipped to serve its large population, and make major inroads into better understanding liver disease.